TMCnet News
Research and Markets: Global Bacterial Endocarditis Active Pharmaceutical Ingredients (API) Insights Report 2015-2016Research and Markets (http://www.researchandmarkets.com/research/mq7ht2/bacterial) has announced the addition of the "Bacterial Endocarditis-API Insights" report to their offering. Bacterial Endocarditis-API Insights, 2015 report provides Bacterial Endocarditis drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Bacterial Endocarditis. The Report provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent, patent exclusivity information and competitie landscape. The research analysis also presents the global sales forecasts data for the Bacterial Endocarditis drugs till 2016. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA (News - Alert) have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China. Companies Mentioned
For more information visit http://www.researchandmarkets.com/research/mq7ht2/bacterial
View source version on businesswire.com: http://www.businesswire.com/news/home/20150817006034/en/ |
